急性缺血性卒中扩展溶栓时间窗:贝叶斯荟萃分析与伞状综述
该系统评价与伞状综述检索了截至2025年8月1日的随机对照试验,比较在先进神经影像辅助下使用阿替普酶或替奈普酶溶栓与标准非溶栓治疗在症状发作时间不明或超过4.5小时的急性缺血性卒中患者中的效果。共纳入6项原始随机试验和7项既往荟萃分析,但均未考虑效用加权改良Rankin量表(uw-mRS)评分或报告直接的获益/风险概率。主要结局uw-mRS的实用等效区域(ROPE)概率为99%,扩展阿替普酶溶栓产生临床获益的概率仅1%;死亡至少增加1例/100例治疗患者的概率为72%。作者认为扩展溶栓时间窗的临床获益存在不确定性,需进一步高质量研究。
要点
- 在症状发作时间不明或超过4.5小时的急性缺血性卒中患者中,借助先进神经影像行扩展阿替普酶溶栓,uw-mRS达到实用等效区域(ROPE)的概率为99%,临床获益概率仅1%。
- 扩展溶栓使死亡至少增加1例/100例治疗患者的概率为72%。
- 共纳入6项原始随机试验和7项既往荟萃分析,但既往分析均未考虑uw-mRS评分,也未报告直接的获益/风险概率。
- 作者认为扩展溶栓时间窗的临床获益存在不确定性,需进一步高质量研究后才可接受进入常规实践。
适用人群与场景
- 症状发作时间不明或超过4.5小时的急性缺血性卒中患者。
研究设计与关键结果
- 研究类型:贝叶斯随机效应荟萃分析及伞状综述,纳入6项原始随机试验和7项既往荟萃分析。
- 干预与对照:在先进神经影像辅助下使用阿替普酶或替奈普酶溶栓 vs 标准非溶栓治疗。
- 主要结局:uw-mRS评分的均数差;扩展阿替普酶溶栓的ROPE概率为99%,临床获益概率仅1%。
- 次要结局:轻微残疾状态的绝对风险差(ARD)和死亡率;扩展溶栓使死亡至少增加1例/100例治疗患者的概率为72%。
- 既往7项荟萃分析均未考虑uw-mRS评分,也未报告直接的获益或风险概率。
证据类型、等级与局限
- 证据类型:随机对照试验的贝叶斯荟萃分析及伞状综述。
- 假设正态-正态层级模型,使用无信息先验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与既往发表的研究不同,本荟萃分析与伞状综述强调扩展溶栓时间窗的临床获益存在不确定性,需进一步高质量研究后才可接受进入常规实践。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: For acute ischemic stroke, national practice guidelines recommend thrombolysis within a 4.5-h time window from symptom onset. Randomized trials with advanced neuroimaging have now examined extended thrombolytic time windows, and multiple meta-analyses have provided positive endorsements. However, these previous meta-analyses have not fully exploited the available data, examined quality of life, or reported the probability of clinically meaningful effects. This meta-analysis addresses these potential shortcomings.
METHODS: We performed a i) systematic literature review up to August 1, 2025, of all randomized controlled trials comparing thrombolysis (alteplase or tenecteplase) with the assistance of advanced neuroimaging to standard, non-thrombolytic therapy in acute ischemic stroke patients with unknown time or beyond 4.5 h since symptom onset and ii) an umbrella review of previous meta-analyses addressing this issue. Our primary outcome was the mean difference in the utility-weighted modified Rankin Scale (uw-mRS) scores. Secondary outcomes were the absolute risk difference (ARD) for minor disability status and mortality. Bayesian random effects meta-analyses were performed assuming a normal-normal hierarchical model with non-informative priors, which permitted probability calculations for benefit, harm, and regions of practical equivalence (ROPE).
RESULTS: Six original randomized trials of extended thrombolysis and 7 meta-analyses were identified but none had considered a uw-mRS score or reported direct probability statements regarding benefit or harm. Our primary uw-mRS outcome showed a ROPE probability of 99 % with only a 1 % probability of a clinically beneficial response with extended alteplase. There was also a 72 % probability that mortality increased by at least 1 life / 100 treated with extended thrombolysis.
CONCLUSIONS: In contrast with previous publications, this meta-analysis and umbrella review highlights the uncertainty of clinical benefits from extended thrombolysis treatment windows and the need for further high-quality research before this treatment is accepted into routine practice.
参考来源
- Garg R, Brophy JM. Extended thrombolysis in acute ischemic stroke: A Bayesian meta-analysis and umbrella review. Am J Emerg Med. 2026. PMID: 41529589. doi:10.1016/j.ajem.2025.12.043
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。